Anti-Wrinkle Efficacy of a Syringic Acid-Containing Emulsion

NCT07850817 | Completed

• 1 other identifier: DPE-HSWIT001(1)-15001
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 1

Brief Summary

This randomized, double-blind, split-face controlled study was conducted to evaluate the anti-wrinkle efficacy and safety of a Syringic acid-containing emulsion in healthy female subjects. The test product was an emulsion containing 2% Synox, a Syringic acid-containing ingredient, while the control product was an emulsion without Synox. Participants applied the test and control products to opposite sides of the face according to random allocation for 12 weeks. Skin wrinkle-related parameters were evaluated at baseline and after 4, 8, and 12 weeks of product use using visual assessment, replica-based instrumental measurement, and subject questionnaires. Skin safety was monitored throughout the study period.

Conditions

Facial Wrinkles; Skin Aging

Keywords

Anti-wrinkle; Syringic acid; Synox; Split-face study; Cosmetic emulsion

Outcome Measures

Primary Outcomes (1)

• Change in Skin Roughness (Rt) (a.u.) After Application of Synox-Containing Emulsion

  Skin roughness (Rt) was assessed from SILFLO skin replicas using a Visioline® VL650 (C+K, Germany). Skin replicas were prepared from the wrinkle-prone test area and analyzed by the instrument to obtain skin surface roughness parameters. Rt was expressed in arbitrary units (a.u.). Changes in Rt from baseline were assessed at Weeks 4, 8, and 12 and compared between the Synox-containing emulsion-treated side and the control emulsion-treated side.

  Baseline, Week 4, Week 8, and Week 12

Secondary Outcomes (2)

• Change in Maximum Skin Roughness (Rm) (a.u.) After Application of Synox-Containing Emulsion

  Baseline, Week 4, Week 8, and Week 12

• Change in Periorbital Wrinkle Assessment Grade After Application of Synox-Containing Emulsion

  Baseline, Week 4, Week 8, and Week 12

Study Arms (2)

Test Emulsion Right / Control Emulsion Left

EXPERIMENTAL

Participants in Group A applied the test emulsion containing Synox on the right side of the face and the control emulsion on the left side of the face according to the randomized split-face allocation.

Other: Synox-containing Emulsion; Other: Control Emulsion

Test Emulsion Left / Control Emulsion Right

EXPERIMENTAL

Participants in Group B applied the test emulsion containing Synox on the left side of the face and the control emulsion on the right side of the face according to the randomized split-face allocation.

Other: Synox-containing Emulsion; Other: Control Emulsion

Interventions

Synox-containing Emulsion OTHER

A cosmetic emulsion containing 2% Synox, a raw material containing 1% Syringic acid, was applied topically for 12 weeks.

Test Emulsion Left / Control Emulsion Right; Test Emulsion Right / Control Emulsion Left

Control Emulsion OTHER

A vehicle control emulsion without Synox was applied to the contralateral side of the face for 12 weeks.

Test Emulsion Left / Control Emulsion Right; Test Emulsion Right / Control Emulsion Left

Eligibility Criteria

• Age: 30 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged 30 to 65 years with facial wrinkles at the test site according to investigator assessment.
• Healthy subjects without acute or chronic systemic diseases, including skin diseases.
• Subjects who voluntarily agreed to participate after receiving sufficient explanation of the study purpose and procedures and provided written informed consent.
• Subjects who were able to comply with study procedures and follow-up visits.

You may not qualify if:

• Subjects who were pregnant, breastfeeding, or planning pregnancy within 6 months.
• Subjects who had used topical products containing steroids for treatment of skin diseases for more than one month.
• Subjects who participated in similar clinical studies within 6 months.
• Subjects with sensitive or hypersensitive skin.
• Subjects with abnormal skin conditions at the test site, including moles, warts, or telangiectasia.
• Subjects who had used similar cosmetics or medicines within 3 months before study initiation.
• Subjects who received or planned cosmetic procedures (e.g., skin peeling, Botox, or other dermatological treatments) within 6 months.
• Subjects with chronic wasting diseases or systemic diseases.
• Subjects considered unsuitable for participation by the investigator.

Sponsors & Collaborators

• BioSpectrum Inc: lead

Study Sites (1)

Dermapro Co., Ltd.

Seoul, 06570, South Korea

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Participants, investigators, care providers, and outcome assessors were blinded to the treatment allocation. The test product and control product were applied according to the randomized split-face allocation scheme.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This study was conducted using a randomized split-face controlled design. Participants were assigned to two groups and applied the test product and control product to opposite sides of the face according to the randomized allocation scheme.

Study Record Dates

• First Submitted: September 18, 2026
• First Posted: September 30, 2026
• Study Start: January 12, 2015
• Primary Completion: April 17, 2015
• Study Completion: April 17, 2015
• Last Updated: September 30, 2026

Record last verified: 2026-09

Locations

KR (1)